UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 224

Sortiert nach

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1794-1802

2009

Link zum Volltext

Verfügbarkeit prüfen

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study

Annals of oncology, 2014-01, Vol.25 (1), p.160-165

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1794

2009

Link zum Volltext

Verfügbarkeit prüfen

Adverse event profile by folate receptor status for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

Gynecologic oncology, 2014-06, Vol.133, p.178-178

2014

Link zum Volltext

Verfügbarkeit prüfen

CA-125 as a response marker for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial

Gynecologic oncology, 2014-06, Vol.133, p.177-178

2014

Link zum Volltext

Verfügbarkeit prüfen

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer

International journal of gynecological cancer, 2017-05, Vol.27 (4), p.832-837

2017

Link zum Volltext

Verfügbarkeit prüfen

8029 POSTER Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) – an Exploratory Analysis

European journal of cancer (1990), 2011, Vol.47, p.S536-S536

2011

Link zum Volltext

Verfügbarkeit prüfen

The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients

International journal of gynecological cancer, 2008-11, Vol.18 (6), p.1279-1284

2008

Link zum Volltext

Verfügbarkeit prüfen

8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials

European journal of cancer (1990), 2011, Vol.47, p.S528-S529

2011

Link zum Volltext

Verfügbarkeit prüfen

I043 THE ROLE OF SURGERY IN RELAPSED OVARIAN CANCER

International journal of gynecology and obstetrics, 2012-10, Vol.119 (S3), p.S171-S171

Bidziński, M.

2012

Link zum Volltext

Verfügbarkeit prüfen

EP894 Evaluation of the clinical usefulness of HE4 and CA125 assays in monitoring treatment response of patients with advanced ovarian cancer

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A483-A484

2019

Link zum Volltext

Verfügbarkeit prüfen

EP386 Cervical cancer screening in PHC organization in poland

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A259-A259

2019

Link zum Volltext

Verfügbarkeit prüfen

Results of chemotherapy for pulmonary metastases of carcinoma of the cervix in patients after primary surgical and radiotherapeutic management

International journal of gynecological cancer, 2007-09, Vol.17 (5), p.1056-1061

2007

Link zum Volltext

Verfügbarkeit prüfen

44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

Annals of oncology, 2022-06, Vol.33, p.S400-S401

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the results of surgical treatment using laparoscopy and laparotomy in patients with endometrial cancer

International journal of gynecological cancer, 2005-09, Vol.15 (5), p.946-951

2005

Link zum Volltext

Verfügbarkeit prüfen

The evaluation of intra‐ and postoperative complications related to debulking surgery with bowel resection in patients with FIGO stage III–IV ovarian cancer

International journal of gynecological cancer, 2007-09, Vol.17 (5), p.993-997

2007

Link zum Volltext

Verfügbarkeit prüfen

Precedent Subset Analysis: Safety and Disease Control with Vintafolide Monotherapy Following Discontinuation of Pegylated Liposomal Doxorubicin (Pld)

Annals of oncology, 2014-09, Vol.25, p.iv312

2014

Link zum Volltext

Verfügbarkeit prüfen

33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial

International journal of gynecological cancer, 2019-09, Vol.29 (Suppl 3), p.A21-A21

2019

Link zum Volltext

Verfügbarkeit prüfen

LONG TERM FOLLOW UP OF BORDERLINE OVARIAN TUMORS IN ONCOLOGIC CENTER IN WARSAW

International journal of gynecological cancer, 2003-03, Vol.13 (Suppl 1), p.43-43

2003

Link zum Volltext

Verfügbarkeit prüfen

Increased cancer risk of heterozygotes with NBS1 germline mutations in poland

International journal of cancer, 2004-08, Vol.111 (1), p.67-71

2004

Link zum Volltext

Verfügbarkeit prüfen

Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumours

Annals of human genetics, 2002-11, Vol.66 (5‐6), p.353-359

2002

Link zum Volltext

Verfügbarkeit prüfen

8064 Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer

European journal of cancer supplements, 2009, Vol.7 (2), p.468-468

2009

Link zum Volltext

Verfügbarkeit prüfen

ADENOCARCINOMA OF THE UTERINE CERVIX: THE ANALYSIS OF PROGNOSTIC FACTORS

International journal of gynecological cancer, 2003-03, Vol.13 (Suppl 1), p.100-100

2003

Link zum Volltext

Verfügbarkeit prüfen

GRANULOSA CELL TUMOR- THE EVALUATION OF SOME CLINICAL AND THERAPEUTIC PARAMETERS AS PROGNOSTIC FACTORS

International journal of gynecological cancer, 2003-03, Vol.13 (Suppl 1), p.50-50

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 224

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(153)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Life Sciences & Biomedicine
(86)
Male
(80)
Humans
(70)
Animals
(62)
Female
(60)
Rats
(58)
Adult
(49)
Middle Aged
(44)
Biological And Medical Sciences
(42)
Neurosciences & Neurology
(34)
Pharmacology & Pharmacy
(32)
Neurosciences
(30)
Rats, Wistar
(30)
Aged
(26)
Medical Sciences
(25)
Behavioral Sciences
(23)
Ovarian Cancer
(21)
Oncology
(19)
Fundamental And Applied Biological Sciences. Psychology
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Adverse event profile by folate receptor status for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

CA-125 as a response marker for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer

The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients

8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials

I043 THE ROLE OF SURGERY IN RELAPSED OVARIAN CANCER

EP894 Evaluation of the clinical usefulness of HE4 and CA125 assays in monitoring treatment response of patients with advanced ovarian cancer

EP386 Cervical cancer screening in PHC organization in poland

Results of chemotherapy for pulmonary metastases of carcinoma of the cervix in patients after primary surgical and radiotherapeutic management

44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

Comparison of the results of surgical treatment using laparoscopy and laparotomy in patients with endometrial cancer

The evaluation of intra‐ and postoperative complications related to debulking surgery with bowel resection in patients with FIGO stage III–IV ovarian cancer

39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer

Precedent Subset Analysis: Safety and Disease Control with Vintafolide Monotherapy Following Discontinuation of Pegylated Liposomal Doxorubicin (Pld)

33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial

LONG TERM FOLLOW UP OF BORDERLINE OVARIAN TUMORS IN ONCOLOGIC CENTER IN WARSAW

Increased cancer risk of heterozygotes with NBS1 germline mutations in poland

Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumours

8064 Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer

ADENOCARCINOMA OF THE UTERINE CERVIX: THE ANALYSIS OF PROGNOSTIC FACTORS

GRANULOSA CELL TUMOR- THE EVALUATION OF SOME CLINICAL AND THERAPEUTIC PARAMETERS AS PROGNOSTIC FACTORS

Suchergebnisse filtern